• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • CTX cells for Stroke Disability
    • CTX cells for Critical Limb Ischaemia
    • hRPCs for Retinitis Pigmentosa
    • CTX-derived Exosomes
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase II clinical trial in stroke disability (PISCES-II)
    • Observational study in stroke
    • Phase I trial in critical limb ischaemia
    • Phase I/II clinical trial in retinitis pigmentosa
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • Webcasts and Presentations
    • Financial Calendar
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • CTX cells for Stroke Disability
    • CTX cells for Critical Limb Ischaemia
    • hRPCs for Retinitis Pigmentosa
    • CTX-derived Exosomes
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase II clinical trial in stroke disability (PISCES-II)
    • Observational study in stroke
    • Phase I trial in critical limb ischaemia
    • Phase I/II clinical trial in retinitis pigmentosa
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • Webcasts and Presentations
    • Financial Calendar
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Pioneering stem cell therapeutics

We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Find out more about ReNeuron

Share Price

More details

5.875p 0.000p

at 2015-07-24 16:25:10

15 minute delayed share price from London Stock Exchange provided by Euroland.

Our Products & Technologies

Lab working look at petri dish Read more

Clinical Trials

hRPCs for Retinitis Pigmentosa Read more

Investor Centre

Investor Centre banner image Read more

Latest News

View all

ReNeuron announces proposed Placing to raise £68.4 million and Notice of General Meeting

Preliminary Results for the Year Ended 31 March 2015

ReNeuron announces research collaboration with Benitec Biopharma using exosomes as delivery system for gene silencing in cancer therapy

Share Price

More details

5.875p 0.000p

at 2015-07-24 16:25:10

15 minute delayed share price from London Stock Exchange provided by Euroland.

Subscribe here for our Press Releases:

© ReNeuron Group plc 2015 All rights reserved

Website design by Carr Kamasa Design

  • Privacy
  • Disclaimer